A post by @FirstSquawk on X.

CVS Health reported third-quarter 2026 adjusted EPS of $2.09, well above the $1.66 consensus, alongside adjusted operating income of $4.19B versus a $3.62B estimate and net revenue of $108.4B that topped the $104.62B forecast. The company raised its full-year adjusted EPS outlook to at least $8.20 from a prior $7.90–$8.10 range against an $8.05 consensus, and lifted its FY revenue guidance to at least $420B from at least $414B. It also guided full-year free cash flow from operations to at least a level disclosed in the full release. The beat-and-raise across earnings, revenue and cash flow signals stronger-than-expected performance in its insurance and pharmacy businesses. Investors will watch whether the upgraded targets hold through the remainder of the year and how management details the drivers behind the raised cash flow outlook.